等待开盘 12-20 09:30:00 美东时间
-0.006
-0.92%
GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low
11-19 20:09
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company's next generation of
11-17 23:17
SCYNEXIS announces resumption of Phase 3 MARIO study following FDA clinical hold lift, with initial patient dosed. GSK to pay $10M milestone now and $20M in six months, despite dispute over payments. Study aims to evaluate oral ibrexafungerp as step-down therapy for invasive candidiasis.
05-28 12:30
复宏汉霖2024年超57亿元营收 3月24日,复宏汉霖发布2024年度业绩,于业绩期内实现营业收入约57.244亿元,较去年同期增长约6.1%,净利润达...
03-25 18:49
北京时间2025年01月03日03时36分,Ironwood医药(IRWD.us)股票出现波动,股价急速下跌5.30%。截至发稿,该股报4.20美元/股,成交量88.5652万股,换手率0.55%,振幅7.34%。 最近的财报数据显示,该股实现营业收入91.59百万美元,净利润3.65百万美元,每股收益0.02美元,毛利91.09百万美元,市盈率-421.50倍。 机构评级方面,在所有6家参与评级的机构中,83%的券商给予买入建议,17%的券商给予持有建议,无券商给予卖出建议。 Ironwood医药股票所在的制药行业中,整体涨幅为0.31%。其相关个股中,Procaps Group S.A. ...
01-03 03:36
北京时间2025年01月03日02时35分,坎伯兰药业(CPIX.us)股票出现异动,股价快速下跌5.06%。截至发稿,该股报2.25美元/股,成交量3.7513万股,换手率0.27%,振幅8.02%。 最近的财报数据显示,该股实现营业收入9.09百万美元,净利润-1.54百万美元,每股收益-0.11美元,毛利6.65百万美元,市盈率-2.96倍。 机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。 坎伯兰药业股票所在的制药行业中,整体涨幅为0.23%。其相关个股中,Biofrontera Inc C/Wts 27/10/2026 (To Pur Com)、Procaps Grou...
01-03 02:35